ArticleCancer medicine2018
A comparison of relative survival and cause-specific survival methods to measure net survival in cancer populations.
Article in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Cancer Patients Mortality From Other Causes: A European Population-Based Study.Cancer medicine · 2026Article
- Long-term relative survival with and without radioiodine in patients with low-risk thyroid cancer: a SEER based analysis of histologic subtypes and risk factors.European journal of nuclear medicine and molecular imaging · 2026Article
- Impact of Radioactive Iodine Treatment on Long-Term Relative Survival in Patients with Papillary and Follicular Thyroid Cancer: A SEER-Based Study Covering Histologic Subtypes and Recurrence Risk Categories.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Sex Difference in 5-year Relative Survival Following Percutaneous Coronary Intervention.European cardiology · 2024Article
- Long-Term Survival in Patients with Cancers: Surveillance, epidemiology and end results-based analysis.Sultan Qaboos University medical journal · 2023Article
- Effects of Curative-Intent Treatments on Hepatocellular Carcinoma Survival in Alcohol-Related Cirrhosis: A Nationwide Study.Clinical epidemiology · 2023Article
- Relative Survival With Early-Stage Breast Cancer in Screened and Unscreened Populations.Mayo Clinic proceedings · 2022Article
- Socioeconomic disparities in colorectal cancer survival: contributions of prognostic factors in a large Australian cohort.Journal of cancer research and clinical oncology · 2022Article
- Survival of Breast Cancer by Stage, Grade and Molecular Groups in Mallorca, Spain.Journal of clinical medicine · 2022Article
- Osteosarcoma: A Surveillance, Epidemiology, and End Results program-based analysis from 1975 to 2017.Cancer · 2022Article
- Prostate Cancer Survival by Risk and Other Prognostic Factors in Mallorca, Spain.International journal of environmental research and public health · 2021Article
- Comparison of Relative Survival and Cause-Specific Survival in Men With Prostate Cancer According to Age and Risk Category: A Nationwide, Population-Based Study.American journal of epidemiology · 2021Article
- Cause of death for patients with breast cancer: discordance between death certificates and medical files, and impact on survival estimates.Archives of public health = Archives belges de sante publique · 2021Article
- Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival.BMC cancer · 2021Article
- A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed.Cancers · 2019Review
- Renal cell carcinoma trends in Latvia: incidence, mortality, and survival rates. Population-based study.Central European journal of urology · 2019Article
- A comparison of relative survival and cause-specific survival methods to measure net survival in cancer populations.Cancer medicine · 2018Article
- Marital status does not affect the cancer-specific survival of patients with upper tract urothelial carcinoma treated with nephroureterectomy: a propensity score matching study.Therapeutic advances in urologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate cancer survival statistics are necessary for describing population-level survival patterns and measuring advancements in cancer care. Net cancer survival is measured using two methods: cause-specific survival (CSS) and relative survival (RS). Both are valid methodologies for estimating net survival and are used widely in medical research. In these analyses, we compare CSS to RS at selected cancer sites.
methodsUsing data from 18 SEER registries between 2000 and 2014, five-year RS and CSS estimates were generated overall as well as by age groups and by sex. To assess how closely the two survival methods corresponded, net survival percent difference was calculated with the following formula: ((RS-CSS)/RS)*100.
resultsDiscrepancies between estimates obtained from CSS and RS methods varied with cancer site and age, but not by sex. In most cases, CSS was greater than RS, but cancers with available early screening and high survival rate had higher RS than CSS. Net survival percent differences were small in children and adolescents and young adults, and large in adults over the age of 40.
conclusionsWhile both CSS and RS aim to quantify net survival, the estimates tend to differ due to the biases present in both methodologies. Error when estimating CSS most frequently stems from misclassification of cause of death, whereas RS is subject to error when no suitable life tables are available. Appropriate use of CSS and RS requires a detailed understanding of the characteristics of the disease that may lead to differences in the estimates generated by these methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.